Paperpal Prime Logo

Lung Cancer : Impact Factor & More

eISSN: 1872-8332pISSN: 0169-5002

Aims and Scope of Lung Cancer

Lung Cancer is a peer-reviewed medical journal published by Elsevier originally published on behalf of the International Association for the Study of Lung Cancer (until 2006). As of 2015, it is published on behalf of the International Lung Cancer Consortium, the European Thoracic Oncology Platform, and the British Thoracic Oncology Group. It includes original research and review articles of relevance to lung cancer. Less

Key Metrics

CiteScore
9.4
Eigenfactor
0.01 - 0.05
H-Index
141
Impact Factor
5 - 10
SJR
Q1Oncology
SNIP
1.44
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Lung Cancer

Lung Cancer Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher ELSEVIER IRELAND LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1985
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Lung Cancer ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Lung Cancer

Comparative efficacy of taletrectinib versus first-generation TKIs in TKI-naïve ROS1+non-small cell lung cancer: A matching-adjusted indirect comparison.
  • 1 Sep 2026
  • Lung cancer (Amsterdam, Netherlands)
Immune signatures in NSCLC associated pleural effusions and implications for prognosis.
  • 7 Aug 2026
  • Lung cancer (Amsterdam, Netherlands)
Coordinated microbial-inflammatory associations in never-smoking lung cancer.
  • 3 Aug 2026
  • Lung cancer (Amsterdam, Netherlands)
Clinical characteristics and management of Li-Fraumeni syndrome-associated lung cancer.
  • 3 Aug 2026
  • Lung cancer (Amsterdam, Netherlands)
Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan.
  • 1 Aug 2026
  • Lung cancer (Amsterdam, Netherlands)
Treatment-free survival after two-year immune checkpoint inhibitor treatment in non-small cell lung cancer: Utilizing the Korean Health Insurance Review and Assessment Service database.
  • 1 Aug 2026
  • Lung cancer (Amsterdam, Netherlands)
Comparative efficacy of taletrectinib versus first-generation TKIs in TKI-naïve ROS1+non-small cell lung cancer: A matching-adjusted indirect comparison.
  • 1 Sep 2026
  • Lung cancer (Amsterdam, Netherlands)
Immune signatures in NSCLC associated pleural effusions and implications for prognosis.
  • 7 Aug 2026
  • Lung cancer (Amsterdam, Netherlands)
Coordinated microbial-inflammatory associations in never-smoking lung cancer.
  • 3 Aug 2026
  • Lung cancer (Amsterdam, Netherlands)
Clinical characteristics and management of Li-Fraumeni syndrome-associated lung cancer.
  • 3 Aug 2026
  • Lung cancer (Amsterdam, Netherlands)
Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan.
  • 1 Aug 2026
  • Lung cancer (Amsterdam, Netherlands)
Treatment-free survival after two-year immune checkpoint inhibitor treatment in non-small cell lung cancer: Utilizing the Korean Health Insurance Review and Assessment Service database.
  • 1 Aug 2026
  • Lung cancer (Amsterdam, Netherlands)

FAQs on Lung Cancer